Abstract: The present invention provides a chromatography medium comprising one or more electrospun polymer nanofibres which in use form a stationary phase comprising a plurality of pores through which a mobile phase can permeate and use of the same.

Abstract: The present invention provides a chromatography medium comprising one or more electrospun polymer nanofibers which form a stationary phase comprising a plurality of pores through which a mobile phase can permeate and use of the same in chromatography, such as the isolation of recombinant proteins, monoclonal antibodies, viral vaccines and plasmid DNA. The invention further provides for the use of the chromatographic medium in a simulated moving bed system.

Abstract: Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

Abstract: Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a compound of general formula I wherein R represents phenyl, thienyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen; X represents a group C?Y, wherein Y stands for

Abstract: The present invention provides a process for preparing a functionalised polymeric chromatography medium, which process comprises (I) providing two or more non-woven sheets stacked one on top of the other, each said sheet comprising one or more polymer nanofibres, (II) simultaneously heating and pressing the stack of sheets to fuse points of contact between the nanofibres of adjacent sheets, and (III) contacting the pressed and heated product with a reagent which functionalises the product of step (II) as a chromatography medium.

Abstract: Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

Abstract: A system for virtual internet protocol (VIP) address migration. The system comprises serving one or more clients connected via a switch router over a network to one or more network gateways. The switch router forwards packets to the VIP address of a first network gateway. If the first network gateway determines a VIP address migration criteria has been reached, the first network gateway may migrate any new traffic associated with a packet flow over to a second network gateway for more efficient processing by inserting a default flow code into the header of the VIP address of the packet. Older packets continue to process on the first network gateway, however new packets are forwarded and processed on the second network gateway. Once the packets being processed on the first network gateway completes, the second network gateway becomes the default network gateway for processing existing and new packets.

Abstract: Methods and apparatus for providing an extended socket API are disclosed. A method for providing a socket API according to an implementation of the invention may include: receiving data at a first network socket; opening a second network socket; associating the first network socket and the second network socket using a socket file descriptor of a client-side connection; and directing the data from the first network socket to the second network socket. When an application service utilizes the socket API, the method may further include processing the data, i.e., performing a service.

Abstract: The present invention provides a chromatography medium comprising one or more electrospun polymer nanofibres which form a stationary phase comprising a plurality of pores through which a mobile phase can permeate and use of the same in chromatography, such as the isolation of recombinant proteins, monoclonal antibodies, viral vaccines and plasmid DNA. The invention further provides for the use of the chromatographic medium in a simulated moving bed system.

Abstract: The subject disclosure is directed towards determining and using effort such as in a fitness/exercise/gaming environment in a way that is substantially independent of a person's height, weight, age, and gender (HWAG) properties. Effort data is recorded that represents a person's effort exerted with respect to performing at least one physical activity, in which effort data is substantially independent of weight, and possibly other HWAG properties. In one aspect, effort duration is used to allow different people to compete against others and/or against established targets/goals substantially equally, independent of a person's HWAG properties.

Abstract: Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a furazanobenzimidazole compound of general formula (I).

Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X1-X3, Y1, Y2, L1, R1 and R2 given below and/or solvates, hydrates, esters and pharmaceutically acceptable salts thereof. Furthermore, the invention relates to the use of said compounds for modulating of the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

Abstract: A system for virtual internet protocol (VIP) address migration. The system comprises serving one or more clients connected via a switch router over a network to one or more network gateways. The switch router forwards packets to the VIP address of a first network gateway. If the first network gateway determines a VIP address migration criteria has been reached, the first network gateway may migrate any new traffic associated with a packet flow over to a second network gateway for more efficient processing by inserting a default flow code into the header of the VIP address of the packet. Older packets continue to process on the first network gateway, however new packets are forwarded and processed on the second network gateway. Once the packets being processed on the first network gateway completes, the second network gateway becomes the default network gateway for processing existing and new packets.

Abstract: Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

Abstract: Compounds according to the general formula (I) wherein X1, X2, X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different, and wherein up to 3 of the group X1, X2, X3 and X4 may be N; A is a 5- or 6-membered aromatic or heteroaromtic cycle containing 1 to 3 heteroatoms selected from the group consisting of N, O and S wherein A may be substituted by 1 to 5 substituents R which may be same or different; their solvates, hydrates, and pharmaceutically acceptable salts for the treatment of a disorder or disease associated with an aberrant activation of Wnt signalling in a mammal selected from a cell proliferative disorder, rheumatoid arthritis, increased bone density, aging or age-related disorders and/or diseases or Dupuytren disease (superficial fibromatosis).

Abstract: Methods and apparatus for providing an extended socket API are disclosed. A method for providing a socket API according to an implementation of the invention may include: receiving data at a first network socket; opening a second network socket; associating the first network socket and the second network socket using a socket file descriptor of a client-side connection; and directing the data from the first network socket to the second network socket. When an application service utilizes the socket API, the method may further include processing the data, i.e., performing a service.

Abstract: An optical tracking system, and method therefor, tracks the movement of an object, such as a pilot's helmet, within an enclosed area, such as a cockpit. The system/method comprises a plurality of light sources fixedly mounted in predefined locations within the enclosed area and a light sensor mounted on the object. Each light source is modulated using a different frequency from the other light sources to make that light source uniquely identifiable. Modulated light from the various light sources is converted by the sensor into an electrical signal. This composite signal is subsequently separated into individual signals based on their unique modulations, and the light source for each signal is identified. The signals are thereafter processed to determine an azimuth and an elevation for the line-of-sight to each light source. The azimuth and elevation information may then be used to determine the position and orientation of the object.

Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X1-X3, Y1, Y2, L1, R1 and R2 given below and/or solvates, hydrates, esters and pharmaceutically acceptable salts thereof. Furthermore, the invention relates to the use of said compounds for modulating of the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

Abstract: An optical tracking system, and method therefor, tracks the movement of an object, such as a pilot's helmet, within an enclosed area, such as a cockpit. The system/method comprises a plurality of light sources fixedly mounted in predefined locations within the enclosed area and a light sensor mounted on the object. Each light source is modulated using a different frequency from the other light sources to make that light source uniquely identifiable. Modulated light from the various light sources is converted by the sensor into an electrical signal. This composite signal is subsequently separated into individual signals based on their unique modulations, and the light source for each signal is identified. The signals are thereafter processed to determine an azimuth and an elevation for the line-of-sight to each light source. The azimuth and elevation information may then be used to determine the position and orientation of the object.

Abstract: A power cord switch adapter including a switch housing, a switch housed within the switch housing, a first connector/conductor end conductively connected to the switch, a second connector/conductor end conductively connected to the switch. The power cord switch adapter may also include an attachment member connected to the switch housing, for attaching the power cord switch adapter to an electronic appliance, for instance an imaging device.